Sanuwave Health (NASDAQ:SNWV) Raised to "Strong-Buy" at Northland Capmk

Key Points

• Sanuwave Health (NASDAQ:SNWV) has been upgraded to a "strong-buy" rating by Northland Capital Markets, reflecting increased investor confidence.
• Several brokerages have also raised their price targets on Sanuwave Health, with an average target of $55.00 per share, indicating strong expected performance.
• The company reported a positive quarterly earnings result, exceeding analyst expectations with an EPS of $0.01 compared to an anticipated loss of ($0.09).

Sanuwave Health (NASDAQ:SNWV - Get Free Report) was upgraded by stock analysts at Northland Capmk to a "strong-buy" rating in a report released on Wednesday,Zacks.com reports. Northland Capmk also issued estimates for Sanuwave Health's Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.20 EPS and FY2026 earnings at $1.00 EPS.

A number of other brokerages also recently issued reports on SNWV. Wall Street Zen raised shares of Sanuwave Health from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. Northland Securities started coverage on shares of Sanuwave Health in a research report on Wednesday, September 3rd. They set an "outperform" rating and a $55.00 price objective for the company. Finally, Roth Capital boosted their price objective on shares of Sanuwave Health from $54.00 to $55.00 and gave the company a "buy" rating in a research report on Friday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $55.00.

Sanuwave Health Stock Performance

NASDAQ:SNWV traded up $0.64 during trading hours on Wednesday, reaching $36.56. The company had a trading volume of 11,395 shares, compared to its average volume of 51,148. Sanuwave Health has a 52 week low of $5.63 and a 52 week high of $46.58. The stock has a market cap of $313.32 million, a price-to-earnings ratio of -4.43 and a beta of 1.39. The company's 50 day simple moving average is $37.53.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last posted its earnings results on Friday, August 8th. The company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.10. The company had revenue of $10.16 million during the quarter, compared to the consensus estimate of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Institutional Trading of Sanuwave Health

Several hedge funds have recently bought and sold shares of SNWV. Solas Capital Management LLC purchased a new stake in Sanuwave Health in the 1st quarter worth $20,658,000. AWM Investment Company Inc. purchased a new stake in Sanuwave Health in the 1st quarter worth $18,153,000. Geode Capital Management LLC purchased a new stake in Sanuwave Health in the 2nd quarter worth $5,184,000. Stonebridge Wealth Management LLC purchased a new stake in Sanuwave Health in the 2nd quarter worth $1,696,000. Finally, Evernest Financial Advisors LLC purchased a new stake in shares of Sanuwave Health during the 2nd quarter valued at about $823,000. Hedge funds and other institutional investors own 42.53% of the company's stock.

About Sanuwave Health

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.